Spending that does not fall in a recession

Pet spending held up through every recent downturn better than almost any other consumer category. Households treat companion animals as family, and the medical spending follows human patterns with roughly a decade of lag.

Historically veterinary care was basic and price sensitive. Insurance penetration, corporate consolidation of practices, and a widening range of available treatments changed both the volume and the sophistication of what gets bought.

The structural driver is demographic and behavioural: more single person households, delayed family formation, and an expectation that a pet receives real medical care rather than palliative treatment.

The technology layer spans point of care diagnostics, companion animal pharmaceuticals including monoclonal antibodies and long acting pain treatments, imaging, telehealth triage, practice management software, and insurance claims processing.

Adoption economics work through the practice. A diagnostic run in the clinic rather than sent to a laboratory generates revenue immediately and improves the visit, which practices adopt readily.

The beneficiaries include animal health pharmaceutical companies, diagnostics makers, practice consolidators, pet insurance underwriters, and the software vendors serving clinics.

The value chain runs from pharmaceutical and diagnostic manufacturers through distributors to practices and owners. Consumables and pharmaceuticals recur; equipment does not.

The overlooked layer includes veterinary distribution, laboratory services, insurance claims administrators, and the staffing platforms addressing the veterinarian shortage.

Competitive dynamics favour firms with clinic relationships and approved products, since veterinary approval pathways are shorter than human ones but still real barriers.

Risks: veterinarian shortage caps volume growth, consumer trade down affects elective procedures, practice consolidation pressures supplier pricing, and pet adoption normalised after its recent surge.

What to watch: practice visit volumes, insurance penetration rates, new companion animal drug approvals, and veterinarian graduation numbers.